NDA 020963 · Sandoz
Timolol Maleate
Timolol Maleate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: May 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Oct 21, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
306
98 Phase 3, 14 recruiting
FAERS reports
7,784
3,677 serious, 439 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 28, 2024.
Timolol GFS 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Timolol GFS is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma ( 1 ).
Mechanism: Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Timolol GFS, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. The precise mechanism of the ocular hypotensive action of Timolol GFS is not...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 8, 2007 Supplement 10 · Efficacy · priority review LetterLabel
- Oct 21, 1998 Original approval · Type 3 - New Dosage Form ReviewPediatric Medical ReviewPediatric Written Request
2 products under this application
- TIMOLOL MALEATE · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB
- TIMOLOL MALEATE · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.
- Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02207621 · 756 participants · Start Jul 2014 · Primary completion Mar 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol maleate Ophthalmic Solution 0.5% BID and 1 more · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Bedminster, New Jersey
AllerganAbbVie (ABBV)
NCT02571712 · 750 participants · Start Nov 10, 2015 · Primary completion Jun 21, 2018
Drug: bimatoprost 0.03% plus timolol 0.5% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558374 · 708 participants · Start Sep 2015 · Primary completion Dec 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol Maleate Ophthalmic Solution 0.5% BID · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01026831 · 643 participants · Start Jan 6, 2010 · Primary completion Sep 17, 2010
Drug: Preservative-Free Tafluprost; Comparator: timolol · For: Open-angle Glaucoma; Ocular Hypertension
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesPivotal-lookingCompleted
Santen OyIndustry
NCT01292460 · 600 participants (planned) · Start Feb 2011 · Primary completion Sep 2012
Drug: Timolol/ FDC/ Placebo/ Tafluprost · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Kuopio, Finland; Oulu, Finland
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02247804 · 594 participants · Start Dec 15, 2014 · Primary completion Feb 19, 2018
Drug: Bimatoprost SR; Active Comparator: Timolol 0.5% and 1 more · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Phoenix, Arizona; Glendale, California; Irvine, California · 106 sites in all
- Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Pivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03519386 · 590 participants · Start Jul 26, 2018 · Primary completion Apr 5, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Sioux Falls, South Dakota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure983
- drug ineffective579
- eye pain441
- fatigue410
- eye irritation362
- dizziness291
- diarrhoea284
- vision blurred268
- nausea260
- off label use260
- headache245
- ocular hyperaemia233
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 158 |
| 2005 | 193 |
| 2006 | 156 |
| 2007 | 142 |
| 2008 | 136 |
| 2009 | 133 |
| 2010 | 202 |
| 2011 | 219 |
| 2012 | 309 |
| 2013 | 108 |
| 2014 | 132 |
| 2015 | 252 |
| 2016 | 294 |
| 2017 | 364 |
| 2018 | 367 |
| 2019 | 399 |
| 2020 | 1,435 |
| 2021 | 409 |
| 2022 | 438 |
| 2023 | 514 |
| 2024 | 516 |
| 2025 | 558 |
| 2026 | 349 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Timolol Maleate (Timolol Maleate/PF)
2024 spending
$9.3M
Beneficiaries
9,480
28,017 claims
Per beneficiary
$977
$3.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $171,392 |
| 2021 | $5,930,854 |
| 2022 | $8,101,964 |
| 2023 | $9,682,202 |
| 2024 | $9,261,267 |
Part D: Timolol Maleate* (Timolol Maleate)
2024 spending
$51.3M
Beneficiaries
837,015
2,958,063 claims
Per beneficiary
$61
$2.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $73,879,256 |
| 2021 | $71,093,138 |
| 2022 | $68,190,043 |
| 2023 | $63,904,505 |
| 2024 | $51,254,561 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial.
Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. · JAMA Dermatol 2021 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis.
Lou H, Wang H, Zong Y, et al. · Curr Med Res Opin 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatments of Epistaxis in Hereditary Hemorrhagic Telangiectasia: Systematic Review and Network Meta-Analysis.
Chitsuthipakorn W, Hoang MP, Kanjanawasee D, et al. · Curr Allergy Asthma Rep 2023 · Systematic Review, Network Meta-Analysis
- Fractional CO2 laser alone versus combined with topical timolol or insulin for acne Scar treatment: a randomized controlled clinical trial.
Saki N, Alavizadeh S, Parvizi MM, et al. · Lasers Med Sci 2025 · Randomized Controlled Trial, Comparative Study
- The mechanism of timolol in lowering intraocular pressure. In the normal eye.
Coakes RL, Brubaker RF · Arch Ophthalmol 1978 · Clinical Trial, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.